BioNTech, Q3 2024

BioNTech SE (BNTX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Advancements ...
BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.
BioNTech SE (NASDAQ:BNTX) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Welcome to BioNTech’s Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations.
BioNTech (BNTX) Scheduled to Post Quarterly Earnings on Monday
BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter.
BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript
Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz director, investor relations. Please go ahead. Michael Horowicz-- Vice President,
Brightcove Inc. (BCOV) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ETCompany ParticipantsMarc DeBevoise - Chief Executive
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Nov 04, 2024, 5:00 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Partici
Marqeta (MQ) Q3 2024 Earnings Call Transcript
At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator instructions] As a reminder, this conference is being recorded.
Forward Air Corporation (FWRD) Q3 2024 Earnings Call Transcript
Welcome to the Forward Air's Third Quarter 2024 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for your questions following the presentation.
BioNTech SE Reports Strong Revenue Growth Amid Rising R&D Costs
BioNTech SE (BNTX) has released an update. BioNTech SE’s quarterly report for the period ending September 30, 2024, reveals a ...
Cautious Outlook on BioNTech SE: Strong Q3 Performance Overshadowed by Uncertain Future in Vaccine Sales and Oncology Pipeline
BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...
FiercePharma23h
BioNTech reports surprising COVID vaccine sales in Q3 but tempers expectations for annual sales
Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...
2,051 Shares in BioNTech SE (NASDAQ:BNTX) Purchased by Mount Yale Investment Advisors LLC
Mount Yale Investment Advisors LLC acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the third quarter, according to the company in its most recent 13F filing with the ...
Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...
Why is Pfizer stock falling after Q3 results?
Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...
BioNTech lowers full-year revenue outlook on COVID-19 seasonality, inventory write-downs
German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...